@moleculexyz.bsky.social
DeSci biopharma IP tokenization protocol.
Fund & shape early-stage research ideas at https://www.molecule.xyz/
Fund & shape early-stage research ideas at https://www.molecule.xyz/
The funding stack for science is being rebuilt.
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
November 14, 2025 at 12:03 AM
The funding stack for science is being rebuilt.
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Latest updates:
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
November 13, 2025 at 5:57 PM
Latest updates:
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
The smallest errors in our genetic code can cause the biggest failures in our cells.
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
November 13, 2025 at 5:57 PM
The smallest errors in our genetic code can cause the biggest failures in our cells.
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
From our screener: @BeeARDai -- an AI-powered multi-agent system mapping the psychedelic frontier.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
November 12, 2025 at 9:01 PM
From our screener: @BeeARDai -- an AI-powered multi-agent system mapping the psychedelic frontier.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
The first human trials for reversing aging are coming.
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
November 11, 2025 at 2:58 PM
The first human trials for reversing aging are coming.
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
Today science sits in silos. Tomorrow it lives in markets.
November 9, 2025 at 2:59 AM
Today science sits in silos. Tomorrow it lives in markets.
From our screener: $AUBRAI -- the world's first BioAgent generating and owning onchain IP.
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
November 5, 2025 at 8:57 PM
From our screener: $AUBRAI -- the world's first BioAgent generating and owning onchain IP.
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Science is still running on feudal infrastructure.
New systems are inevitable.
New systems are inevitable.
November 2, 2025 at 1:58 AM
Science is still running on feudal infrastructure.
New systems are inevitable.
New systems are inevitable.
Traditional science funding is in crisis.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
October 30, 2025 at 11:03 PM
Traditional science funding is in crisis.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
Last week, an AI model imagined a cancer treatment -- and got it right.
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
October 28, 2025 at 2:04 PM
Last week, an AI model imagined a cancer treatment -- and got it right.
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
We’re optimizing for safety, not discovery -- producing endless variations of the same drug.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
October 27, 2025 at 3:28 PM
We’re optimizing for safety, not discovery -- producing endless variations of the same drug.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
For a decade, US Supreme Court rulings pulled biotech inventions into "abstract ideas".
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
October 23, 2025 at 11:20 PM
For a decade, US Supreme Court rulings pulled biotech inventions into "abstract ideas".
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
The model predicted that a known cancer drug under specific immune context, could make “cold” tumors visible to the immune system.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
October 21, 2025 at 2:01 PM
The model predicted that a known cancer drug under specific immune context, could make “cold” tumors visible to the immune system.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
An AI model just made -- and experimentally proved -- a new cancer discovery.
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
October 21, 2025 at 2:01 PM
An AI model just made -- and experimentally proved -- a new cancer discovery.
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
If developers spent 80% of their time applying to buy a keyboard, tech would be stuck in 1995.
That’s science today -- researchers spend 80% of their time chasing grants, not breakthroughs.
DeSci aims to fix this.
That’s science today -- researchers spend 80% of their time chasing grants, not breakthroughs.
DeSci aims to fix this.
October 14, 2025 at 1:58 PM
If developers spent 80% of their time applying to buy a keyboard, tech would be stuck in 1995.
That’s science today -- researchers spend 80% of their time chasing grants, not breakthroughs.
DeSci aims to fix this.
That’s science today -- researchers spend 80% of their time chasing grants, not breakthroughs.
DeSci aims to fix this.
the longest-living rodent on Earth lives 10x longer than its peers.
now we know why.
a new science paper shows 4 amino acid changes in naked mole-rat cGAS flip a biological switch.
from immune triggering ➝ to DNA repairing
longevity isn't fiction, it's an engineering problem.👇
now we know why.
a new science paper shows 4 amino acid changes in naked mole-rat cGAS flip a biological switch.
from immune triggering ➝ to DNA repairing
longevity isn't fiction, it's an engineering problem.👇
October 13, 2025 at 11:02 PM
the longest-living rodent on Earth lives 10x longer than its peers.
now we know why.
a new science paper shows 4 amino acid changes in naked mole-rat cGAS flip a biological switch.
from immune triggering ➝ to DNA repairing
longevity isn't fiction, it's an engineering problem.👇
now we know why.
a new science paper shows 4 amino acid changes in naked mole-rat cGAS flip a biological switch.
from immune triggering ➝ to DNA repairing
longevity isn't fiction, it's an engineering problem.👇
With Molecule Labs, every milestone, event, and research update is tracked transparently onchain.
October 8, 2025 at 2:40 AM
With Molecule Labs, every milestone, event, and research update is tracked transparently onchain.
$VITASTEM is live on Molecule!
Aging starts in your blood.
$VITASTEM is the first @Aubrai_-generated IP Token targeting your body’s blood-forming stem cells -- the source of age-related decline. 👇
Aging starts in your blood.
$VITASTEM is the first @Aubrai_-generated IP Token targeting your body’s blood-forming stem cells -- the source of age-related decline. 👇
October 8, 2025 at 2:40 AM
$VITASTEM is live on Molecule!
Aging starts in your blood.
$VITASTEM is the first @Aubrai_-generated IP Token targeting your body’s blood-forming stem cells -- the source of age-related decline. 👇
Aging starts in your blood.
$VITASTEM is the first @Aubrai_-generated IP Token targeting your body’s blood-forming stem cells -- the source of age-related decline. 👇
Every step on the roadmap is transparently tracked onchain via Molecule Labs and open to anyone.
October 6, 2025 at 3:29 PM
Every step on the roadmap is transparently tracked onchain via Molecule Labs and open to anyone.
$DICK is live on Molecule!
@D1ckGPT is a BioAgent transforming men's health from taboo ➝ testable
Designed to give recommendations for men's health optimization while collecting verifiable data to fuel research breakthroughs. 👇
@D1ckGPT is a BioAgent transforming men's health from taboo ➝ testable
Designed to give recommendations for men's health optimization while collecting verifiable data to fuel research breakthroughs. 👇
October 6, 2025 at 3:29 PM
$DICK is live on Molecule!
@D1ckGPT is a BioAgent transforming men's health from taboo ➝ testable
Designed to give recommendations for men's health optimization while collecting verifiable data to fuel research breakthroughs. 👇
@D1ckGPT is a BioAgent transforming men's health from taboo ➝ testable
Designed to give recommendations for men's health optimization while collecting verifiable data to fuel research breakthroughs. 👇
for centuries, research agendas were set by a handful of governments and wealthy donors.
@paulkhls & @CryptoHayes discuss how DeSci rewrites that script.
> blockchain turns community capital into research power.
> funding flows where people believe discovery matters most.
@paulkhls & @CryptoHayes discuss how DeSci rewrites that script.
> blockchain turns community capital into research power.
> funding flows where people believe discovery matters most.
October 3, 2025 at 10:58 PM
for centuries, research agendas were set by a handful of governments and wealthy donors.
@paulkhls & @CryptoHayes discuss how DeSci rewrites that script.
> blockchain turns community capital into research power.
> funding flows where people believe discovery matters most.
@paulkhls & @CryptoHayes discuss how DeSci rewrites that script.
> blockchain turns community capital into research power.
> funding flows where people believe discovery matters most.
⏳ science runs on long cycles.
⚡ crypto runs on short attention spans.
at DeSci Summit Singapore, @CryptoHayes & our CEO @paulkhls unpacked how to bridge that gap:
> radical transparency: sharing progress, setbacks, and roadmaps with your community.
⚡ crypto runs on short attention spans.
at DeSci Summit Singapore, @CryptoHayes & our CEO @paulkhls unpacked how to bridge that gap:
> radical transparency: sharing progress, setbacks, and roadmaps with your community.
October 3, 2025 at 1:02 PM
⏳ science runs on long cycles.
⚡ crypto runs on short attention spans.
at DeSci Summit Singapore, @CryptoHayes & our CEO @paulkhls unpacked how to bridge that gap:
> radical transparency: sharing progress, setbacks, and roadmaps with your community.
⚡ crypto runs on short attention spans.
at DeSci Summit Singapore, @CryptoHayes & our CEO @paulkhls unpacked how to bridge that gap:
> radical transparency: sharing progress, setbacks, and roadmaps with your community.
$26T a year -- lost to diseases we already know how to prevent.
the science exists, but remains underfunded + underimplemented.
the problem isn't ideas. it's infrastructure 👇
the science exists, but remains underfunded + underimplemented.
the problem isn't ideas. it's infrastructure 👇
September 29, 2025 at 11:04 PM
$26T a year -- lost to diseases we already know how to prevent.
the science exists, but remains underfunded + underimplemented.
the problem isn't ideas. it's infrastructure 👇
the science exists, but remains underfunded + underimplemented.
the problem isn't ideas. it's infrastructure 👇
IP Tokens offer an open, permissionless, decentralized way to fund scientific research onchain -- and then what?
We're designing the DeSci value flywheel; complete economic cycles where scientific breakthroughs fuel the next generation of discoveries
🧵 ⤵️
We're designing the DeSci value flywheel; complete economic cycles where scientific breakthroughs fuel the next generation of discoveries
🧵 ⤵️
September 29, 2025 at 4:54 PM
IP Tokens offer an open, permissionless, decentralized way to fund scientific research onchain -- and then what?
We're designing the DeSci value flywheel; complete economic cycles where scientific breakthroughs fuel the next generation of discoveries
🧵 ⤵️
We're designing the DeSci value flywheel; complete economic cycles where scientific breakthroughs fuel the next generation of discoveries
🧵 ⤵️